Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events Journal Article
| Authors: | Jäger, E.; Stockert, E.; Zidianakis, Z.; Chen, Y. T.; Karbach, J.; Jäger, D.; Arand, M.; Ritter, G.; Old, L. J.; Knuth, A. |
| Article Title: | Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events |
| Abstract: | Humoral immune responses against the "Cancer-Testis" (CT) antigen NY-ESO-1 are frequently observed in patients with NY-ESO-1 expressing tumors. This is in contrast to other known tumor antigens (TA) defined by antibody or cytotoxic T cell (CTL) reactivity, i.e., MAGE-1, MAGE-3, SSX2, Melan A, and tyrosinase. No NY-ESO-1 antibody has been detected in healthy controls and patients with NY-ESO-1 negative tumors. In this study, we have assessed the NY-ESO-1 serum antibody response in patients with NY-ESO-1 positive tumors of different histological types and stages using Western blotting and an ELISA. Of the 12 patients analyzed, 10 had demonstrable NY-ESO-1 antibodies at the start of the study. All patients were followed for changes in NY-ESO-1 antibody titers during the course of tumor treatment and clinical evolution. In 4 patients, an increase of NY-ESO-1 antibody titer was observed with progression of disease or extensive tumor necrosis under treatment. One patient showed a stable NY-ESO-1 antibody titer over 3 years along with gradual regression of a large tumor mass. In 5 patients, a decrease of NY-ESO-1 antibody was detected: in 1 patient after curative tumor resection, in 3 patients with partial regression of metastatic disease under chemo- and immunotherapy, and in another patient with a NY-ESO-1 negative tumor relapse. Our results indicate that the induction and maintenance of NY-ESO-1 antibody is dependent on the presence of NY-ESO-1 expressing tumors. Furthermore, changes in NY-ESO-1 antibody titers correlate with the evolution of NY-ESO-1 positive disease. Int. J. Cancer (Pred. Oncol.) 84:506-510, 1999. (C) 1999 Wiley-Liss, Inc. |
| Keywords: | gene; protein; peptide; carcinoma; antibodies; identification; cytolytic t-lymphocytes; human-melanoma; definition; human tumor-antigens |
| Journal Title: | International Journal of Cancer |
| Volume: | 84 |
| Issue: | 5 |
| ISSN: | 0020-7136 |
| Publisher: | John Wiley & Sons |
| Date Published: | 1999-10-22 |
| Start Page: | 506 |
| End Page: | 510 |
| Language: | English |
| ACCESSION: | WOS:000082967100010 |
| DOI: | 10.1002/(sici)1097-0215(19991022)84:5<506::aid-ijc10>3.0.co;2-6 |
| PROVIDER: | wos |
| PUBMED: | 10502728 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work